The gut responds to higher drug concentrations by speeding things along
Lilly says it plans full presentation at a scientific congress later this year, and the FDA filing will follow on a schedule the company has not yet specified publicly
Gastrointestinal side effects causing dehydration or non-adherence should be addressed promptly to maintain safe anticoagulation
This approval marked the first oral GLP-1 RA indicated specifically for obesity, creating a new option for patients and clinicians who prefer or require non-injectable therapies, in contrast to Rybelsus, an oral semaglutide approved for the treatment of type 2 diabetes
Beyond primary care, the growth of digital and remote prescribing channels has broadened access to GLP-1 therapies significantly, reaching patients who may not easily access specialist weight management services through traditional routes
Additionally, the caloric restriction associated with weight loss may result in insufficient protein intake, depriving hair follicles of the amino acids needed for keratin synthesis